Tom Marino

Did You Know The Senate Confirmed A Trump Nominee Who Favors Slavery-- For A Lifetime Judicial Position?

This is the pro-slavery judgeLuckily for America-- if not for the folks in PA-10 (Williamsport, Towanda and poor Stroudsburg, where I used to live)-- Tom Marino's nomination to be Drug Czar was withdrawn hours after the 60 Minutes/Washington Post exposé on Marino's role in helping predatory drug manufacturers explode the p

Not EVERYTHING Horrible And Disgusting In Government Can Be Blamed On Trump: Opioids

Tom Marino, the corrupt drug kingpin Trump wants to make Drug CzarWhen you look at the list of the 30 counties with the worst prescription drug abuse problems in America-- counties where people are overdosing and dying from opioids like oxycodone, hydromorphone, codeine and fentanyl, you are also looking at a list of the counties in the Trumpist heartland that elected Trump president of the rest of us.

Chris Carney, One Of The Worst Blue Dogs Ever, Wants To Ride The Anti-Trump Wave Back To Congress

I thought that Denny Heck and Cheri Bustos, respectively, the chair and vic-chair of the DCCC recruitment committee, had the worst idea ever when they tried to recruit corrupt conservative party boy Patrick Murphy to run for the open Miami seat that is being abandoned by Ileana Ros-Lehtinen.

Why Tom Marino Really Turned Down Trump's Offer To Make Him Drug Czar

Wednesday Rep. Tom Marino (R-PA) withdrew his name from consideration as drug czar for Señor Trumpanzee's crackpot Regime. Marino cited his mother's heart problems and dementia as the reason. Were it not for his mother's condition, Marino said he would have accepted Trump's offer to head the drug policy office. "I can't live in D.C.

Trump’s Drug Czar Pick Is A Pharmaceutical Industry Darling

Thomas Marino, U.S. Representative for Pennsylvania’s 10th congressional districts, is interviewed in his office in Washington, D.C. Jan. 2, 2012 (Jake Danna Stevens, The Times-Tribune/AP
President Donald Trump’s reported choice to serve as Director of the Office of National Drug Control Policy has raised alarm concerning conflict of interest, as his top pick has been criticized for protecting and benefiting from the pharmaceutical industry.